Cytori Therapeutics (CYTX) & Meridian Bioscience (VIVO) Financial Analysis
Meridian Bioscience (NASDAQ: VIVO) and Cytori Therapeutics (NASDAQ:CYTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.
This is a summary of recent recommendations and price targets for Meridian Bioscience and Cytori Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Meridian Bioscience currently has a consensus price target of $14.33, indicating a potential upside of 2.02%. Cytori Therapeutics has a consensus price target of $3.65, indicating a potential upside of 1,030.03%. Given Cytori Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cytori Therapeutics is more favorable than Meridian Bioscience.
Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.6%. Cytori Therapeutics does not pay a dividend. Meridian Bioscience pays out 98.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Valuation & Earnings
This table compares Meridian Bioscience and Cytori Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Meridian Bioscience||$198.07 million||2.99||$52.80 million||$0.51||27.55|
|Cytori Therapeutics||$8.75 million||1.28||-$17.75 million||($1.02)||-0.32|
Meridian Bioscience has higher revenue and earnings than Cytori Therapeutics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Meridian Bioscience has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 2.9, meaning that its stock price is 190% more volatile than the S&P 500.
Insider & Institutional Ownership
87.3% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 11.8% of Cytori Therapeutics shares are owned by institutional investors. 2.3% of Meridian Bioscience shares are owned by company insiders. Comparatively, 2.6% of Cytori Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Meridian Bioscience and Cytori Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Meridian Bioscience beats Cytori Therapeutics on 9 of the 15 factors compared between the two stocks.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.